> But for cancer drugs, that really shouldn't be the case. The elasticity isn't in the amount, but in whether the patient obtains the drug. If there are few p

> But for cancer drugs, that really shouldn't be the case. The elasticity isn't in the amount, but in whether the patient obtains the drug. If there are few patients, the demand would be low.